# Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy Participants

> **NCT04991571** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 27 (actual)

## Conditions studied

- Chronic Kidney Disease

## Interventions

- **DRUG:** Zibotentan (Treatment A)
- **DRUG:** Dapagliflozin (Treatment A)
- **DRUG:** Zibotentan/Dapagliflozin - Formulation 1 (Treatment B)
- **DRUG:** Zibotentan/Dapagliflozin - Formulation 2 (Treatment C)

## Key facts

- **NCT ID:** NCT04991571
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-29
- **Primary completion:** 2021-10-22
- **Final completion:** 2021-10-22
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2021-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04991571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04991571, "Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy Participants". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04991571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*